Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells
Abstract
Background/aims
Vascular endothelial growth factor (VEGF) is a key factor in the pathogenesis of neovascular retinal diseases including age-related macular degeneration. VEGF inhibitors including ranibizumab, pegaptanib or bevacizumab improve retinal morphology and vision in many patients. The recently approved drug aflibercept (VEGF Trap-Eye/Eyelea, Regeneron, Tarrytown, New York, USA) offers a new therapy modality. We therefore tested...Paper Details
Title
Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells
Published Date
May 17, 2013
Volume
97
Issue
7
Pages
917 - 923
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History